NSC 23766

Research use only, not for human use.

A specific small molecule inhibitor of Rac GTPase.

A specific small molecule inhibitor of Rac GTPase; potently blockes serum or PDGF-induced Rac1 activation and lamellipodia formation without affecting the activity of endogenous Cdc42 or RhoA; inhibits the proliferation, anchorage-independent growth and invasion phenotypes of human prostate cancer PC-3 cells.

NSC 23766 (100?μM) treatment effectively inhibits polar body emission in a dose-dependent manner. NSC 23766 (200 μM) increases the percentage of morphologically abnormal spindles of oocytes. In NSC 23766-treated oocytes, the p-MAPK protein expression is significantly decreased. NSC23766 (50?μM) plus 100?ng/mL Jagged1, GDF9 and BMP15, reduces the number of germLine cell cysts and increases the number of primordial follicles. NSC23766 significantly inhibits GTP-Rac1 activity and phosphorylation of Rac1-PAK, ERKs and p38 MAPK in the spinal dorsal horn neurons.

NSC23766 (2.5 mg/kg/day, i.p.) significantly attenuates the onset of spontaneous diabetes in NOD mice, without significant effects on the growth (body weights) of the mice. NSC23766 significantly increases the expression of Rac1 and CHOP, a marker for ER-stress, in islets from NOD mice.

NSC-23766 | NSC23766

MAPK/ERK Signaling

Ras

Ras

Cancer

——

733767-34-5

421.5816

C24H35N7

>98% (HPLC)

10 mM in DMSO

CCN(CC)CCCC(C)NC1=NC(=CC(=N1)NC2=CC3=C(C=C(N=C3C=C2)C)N)C

4,6-Quinolinediamine, N6-[2-[[4-(diethylamino)-1-methylbutyl]amino]-6-methyl-4-pyrimidinyl]-2-methyl-

(-20℃)

With Ice Pack

≥ 2 years